Factors influencing the choice of continuous vs time-limited therapy in CLL
Автор: VJHemOnc – Video Journal of Hematology & HemOnc
Загружено: 2026-03-10
Просмотров: 20
Описание:
Barbara Eichhorst, MD, University Hospital Cologne, Cologne, Germany, discusses factors influencing the choice between continuous and time-limited therapy in chronic lymphocytic leukemia (CLL), including treatment convenience and the potential benefits of continuous BTK inhibitor therapy for patients with high-risk disease such as TP53 mutations or del(17p). This interview took place at the ESH CLL 2026 congress in Stockholm, Sweden.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.
Повторяем попытку...
Доступные форматы для скачивания:
Скачать видео
-
Информация по загрузке:
